Form 13-F position report

ARBUTUS BIOPHARMA CORP

Reported by MORGAN STANLEY

ABUS CUSIP 03879J100 Manager CIK 0000895421

Reported 18,376,046 shares, up 677,741 (3.8%) from the prior quarter.

Reported value 3.4%; share count 3.8% vs. the prior quarter.

Added
% of reported 13F value < 0.01% This manager · Q3 2026
Shares 18,376,046 Quarter-end amount reported
Reported value $87,837,503 Fair value at quarter end
Consecutive quarters held 45 Through Q3 2026

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 930000
2022-03-31 587000
2022-06-30 594000
2022-09-30 405000
2022-12-31 563614
2023-03-31 14794298
2023-06-30 11684682
2023-09-30 10680093
2023-12-31 17460282
2024-03-31 22782167
2024-06-30 64767230
2024-09-30 83577536
2024-12-31 73859222
2025-03-31 83035438
2025-06-30 74661764
2025-09-30 111005778
2025-12-31 128440353
2026-03-31 116511663
2026-06-30 84951868
2026-09-30 87837503

Quarterly position history

How this manager's reported quarter-end position changed over time.

20 quarters
Quarterly reported position history for ARBUTUS BIOPHARMA CORP held by MORGAN STANLEY.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2026 Added 18,376,046 +677,741 (3.8%) < 0.01% $87,837,503 2026-11-13
Q2 2026 Reduced 17,698,305 -8,193,175 (-31.6%) < 0.01% $84,951,868 2026-08-13
Q1 2026 Reduced 25,891,480 -811,296 (-3.0%) < 0.01% $116,511,663 2026-05-15
Q4 2025 Added 26,702,776 +2,252,164 (9.2%) < 0.01% $128,440,353 2026-02-13
Q3 2025 Added 24,450,612 +288,229 (1.2%) < 0.01% $111,005,778 2025-11-14
Q2 2025 Added 24,162,383 +369,994 (1.6%) < 0.01% $74,661,764 2025-08-15
Q1 2025 Added 23,792,389 +1,205,471 (5.3%) < 0.01% $83,035,438 2025-05-15
Q4 2024 Added 22,586,918 +878,467 (4.0%) < 0.01% $73,859,222 2025-02-14
Q3 2024 Added 21,708,451 +748,183 (3.6%) < 0.01% $83,577,536 2024-11-14
Q2 2024 Added 20,960,268 +12,129,971 (137.4%) < 0.01% $64,767,230 2024-08-14
Q1 2024 Added 8,830,297 +1,846,185 (26.4%) < 0.01% $22,782,167 2024-05-15
Q4 2023 Added 6,984,112 +1,722,982 (32.7%) < 0.01% $17,460,282 2024-02-13
Q3 2023 Added 5,261,130 +180,834 (3.6%) < 0.01% $10,680,093 2023-11-15
Q2 2023 Added 5,080,296 +197,689 (4.0%) < 0.01% $11,684,682 2023-08-14
Q1 2023 Added 4,882,607 +4,640,713 (1918.5%) < 0.01% $14,794,298 2023-05-15
Q4 2022 Added 241,894 +29,888 (14.1%) < 0.01% $563,614 2023-02-14
Q3 2022 Reduced 212,006 -6,667 (-3.0%) < 0.01% $405,000 2022-11-14
Q2 2022 Added 218,673 +21,492 (10.9%) < 0.01% $594,000 2022-08-15
Q1 2022 Reduced 197,181 -41,826 (-17.5%) < 0.01% $587,000 2022-05-13
Q4 2021 Added 239,007 +17,823 (8.1%) < 0.01% $930,000 2022-02-14
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

234 managers reported ARBUTUS BIOPHARMA CORP for Q3 2026.

Managers reporting ARBUTUS BIOPHARMA CORP in Q3 2026.
Manager Activity Shares Change % of reported 13F Reported value Tenure
MORGAN STANLEY This report Added 18,376,046 +677,741 < 0.01% $87,837,503 45 qtrs
BlackRock Inc Added 14,515,428 +749,357 < 0.01% $69,383,746 9 qtrs
NOMURA HOLDINGS INC Added 14,512,000 +12,874,919 0.08% $69,367,360 6 qtrs
Two Seas Capital LP Reduced 8,143,994 -10,951,589 0.45% $38,928,291 20 qtrs
STATE STREET CORPORATION Reduced 7,081,502 -787,677 < 0.01% $33,849,580 45 qtrs
VANGUARD CAPITAL MANAGEMENT LLC Reduced 6,988,183 -22,496 < 0.01% $33,403,515 3 qtrs
GEODE CAPITAL MANAGEMENT LLC Added 4,121,119 +3,428 < 0.01% $19,703,115 45 qtrs
Rubric Capital Management LP Reduced 3,343,932 -4,189,005 0.15% $15,983,995 10 qtrs
MILLENNIUM MANAGEMENT LLC New 3,061,019 +3,061,019 < 0.01% $14,631,671 30 qtrs
The Goldman Sachs Group Inc Reduced 2,580,551 -926,251 < 0.01% $12,335,034 45 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
September 30, 2026
Filed
November 13, 2026
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
17,735,544
Shared
615,386
None
25,116

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.